Holding

Phoenix Holdings Publishes Financial Statements for Q4 and 2023

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Business, Insurance, Finance, Asset Management, Consulting, Banking, Friends, The Phoenix Companies, Growth, Memory, Share repurchase, Corporation, Policy, TLV, Acquisition, Tel Aviv Stock Exchange, Life, Credit, Solvency, Asset management, Report, SME, Analyst, Safety, Barzilai Medical Center, P&C, Holding, Collection, Pain, Rehabilitation, Mobile phone

Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.

Key Points: 
  • Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.
  • Phoenix is financially resilient with high levels of liquidity and a high Solvency II ratio for Phoenix Insurance, which reached 209% with transitional measures as of September 30, 2023.
  • Comprehensive income before tax in 2023 amounted to NIS 241 million, compared to NIS 235 million in 2022.
  • Comprehensive income before tax in 2023 amounted to NIS 307 million, compared to NIS 300 million in 2022.

Crow Holdings Announces Manufactured Housing Portfolio Acquisition

Retrieved on: 
Thursday, March 21, 2024
Residential Building & Real Estate, Construction & Property, REIT, Acquisition, CHC, Housing, Investment, Manufactured housing, Safety, Lighting, Holding, Basketball, Crow Holdings, Cryptocurrency

Crow Holdings, a leading national real estate investment and development firm, announced today the acquisition of a privately owned 46-property, 9,838-pad, all-age manufactured housing portfolio across Ohio, Missouri, Illinois, Indiana, Montana, and Florida.

Key Points: 
  • Crow Holdings, a leading national real estate investment and development firm, announced today the acquisition of a privately owned 46-property, 9,838-pad, all-age manufactured housing portfolio across Ohio, Missouri, Illinois, Indiana, Montana, and Florida.
  • The acquisition was made through Crow Holdings’ investment management company Crow Holdings Capital (“CHC”) and acquired on behalf of investors in Crow Holdings Realty Partners X, L.P. (“The Fund”), which closed in February 2024 with $3.1 billion of commitments.
  • “Given the high cost of homeownership driven by increasing home prices and mortgage rates, manufactured housing communities are extremely attractive options for residents,” said Bob McClain, CEO of Crow Holdings Capital.
  • “Crow Holdings’ depth of experience in the sector has provided us with the relationships and capabilities to build a market-leading, nationwide manufactured housing platform.

mmERCH Secures $6.4m in Seed Investment to Further Blockchain-Enabled 1-of-1 Clothing Collections

Retrieved on: 
Thursday, March 14, 2024
Technology, Retail, Web3, Blockchain, Online Retail, Luxury, Other Technology, Other Retail, Telecommunications, Internet, Data Management, Security, Consumer Electronics, Fashion, Philosophy, Ideation, AI, Life, Creativity, Multimedia, Holding, Collection, Artificial intelligence, Individual, Cryptocurrency

View the full release here: https://www.businesswire.com/news/home/20240314922365/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240314922365/en/
    Founder and CEO of mmERCH, Colby Mugrabi (Photo: Business Wire)
    Revealed in late 2023 by Founder and CEO Colby Mugrabi, mmERCH is supported by a hand-picked team of founders, creators, collectors, curators, artists, academics, and authors.
  • This fundraise announcement comes as mmERCH is set to release their inaugural collection in April 2024.
  • This investment marks a strong step towards realizing our vision of 'neo-couture,’ offering collections of unique, one-of-a-kind products that have evolving digital and physical utility.
  • mmERCH is challenging convention in every aspect of the fashion industry, from ideation to supply chain to the customer experience.

PENDULUM® Announces the Branding of its Strategic Advisory Services with the Launch of Pendulum Sports & Entertainment

Retrieved on: 
Thursday, March 14, 2024
Content Marketing, General Sports, Sports, Entertainment, Consulting, Advertising, Communications, Professional Services, General Entertainment, MSD, EPL, Negotiation, Culture, Sport, BDT, Partnership, Branding, LLP, Athlete, MLS, NWSL, MLB, Ecosystem, Partner, Holding, NBA, Family, Reinforcement learning

Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.

Key Points: 
  • Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.
  • PSE serves as a transformative bridge between its clients’ brands and their most significant business ambitions and endeavors.
  • Founded in 2019 by D’Rita and Robbie Robinson, Pendulum seeks to reimagine how great companies are built and redefine who gets to build them.
  • “The launch of PSE demonstrates continued momentum in our business and is a significant milestone for Pendulum.

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib

Retrieved on: 
Wednesday, March 13, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Brain, NSCLC, New Drug Application, Patient, JAMA Oncology, NDA, Anaplastic lymphoma kinase, Crizotinib, Safety, File, Holding, Food, ALK, PDUFA, Pharmaceutical industry

Xcovery Holdings, Inc. , an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).

Key Points: 
  • Xcovery Holdings, Inc. , an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
  • The filing is based on the results of the eXalt3, a randomized global phase III study designed to evaluate the efficacy and safety of ensartinib vs crizotinib in the first-line treatment of ALK-positive NSCLC.
  • The FDA granted the application Standard Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2024.
  • In the clinical trials, the drug has demonstrated robust and durable responses in ALK-positive NSCLC patients (both systemically and in the brain), with an extensively studied and well manageable safety profile.

Maiden Holdings, Ltd. Releases Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
Banking, Asset Management, Professional Services, Finance, Holding

Maiden Holdings, Ltd. (NASDAQ:MHLD) ("Maiden") has released its fourth quarter 2023 financial results via its investor relations website.

Key Points: 
  • Maiden Holdings, Ltd. (NASDAQ:MHLD) ("Maiden") has released its fourth quarter 2023 financial results via its investor relations website.
  • Concurrent with releasing its results, Maiden also published an investor update presentation.
  • Both documents are posted at https://www.maiden.bm/investor_relations .

TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

Retrieved on: 
Tuesday, April 2, 2024
PLC, Patient, TCB, Holding, Doctor of Philosophy, Senior, Cancer, TC, Commercialization, Process

This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment.

Key Points: 
  • This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment.
  • The Company expects to implement the improved manufacture process into its current facility in the next 24 months.
  • "These new initiatives will allow us to increase capacity while simultaneously reducing the cost of our per patient treatment once optimized," said Dr. Lauren Bor, Ph.D., Process Development and Commercialization, Senior Manager.
  • Additionally, I believe that these developments will lay the groundwork for commercialization plan and increasing TC BioPharm's manufacturing footprint."

TCBP Announces Exercise of Series D Warrants For Cash

Retrieved on: 
Monday, March 18, 2024
PLC, Series, Holding, American depositary receipt, Exercise, Cancer, AML, ADS, Security (finance)

EDINBURGH, Scotland, March 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares (ADS) at an exercise price of $2.02.

Key Points: 
  • The gross proceeds of the warrant exercise was $1,263,000 with a net cash infusion of $1,168,275 to the Company post fees associated with the exercise to HC Wainwright & Co.
  • There was no additional consideration or inducement paid for the exercise of the Series D warrants in this transaction.
  • "This transaction is further reflective of the promise of TCB-008 and The Company as whole," stated CEO Bryan Kobel.
  • "We will continue to execute on our 2024 plan, driving to human data in AML as well as expanding our platform.

CLAIRE'S ANNOUNCES NATIONAL LAUNCH IN WALGREENS

Retrieved on: 
Tuesday, March 12, 2024
Cosmetics, Holding, Love, Pharmacy

HOFFMAN ESTATES, Ill., March 12, 2024 /PRNewswire/ -- Claire's Holdings LLC today announces a collaboration with integrated healthcare, pharmacy and retail leader Walgreens to bring the brand's assortment of fashion accessories and products to more than 4,400 Walgreens locations nationwide by the end of this month.

Key Points: 
  • Through this launch, Claire's best-selling jewelry, hair accessories and cosmetics, as well as seasonal pieces, will now be accessible to even more shoppers, bringing them the products they love at the convenience of their nearest Walgreens.
  • Each participating Walgreens location will have a dedicated display of trend-forward products located within the seasonal section of the store that are merchandised by Claire's.
  • "As a one-stop destination for everyday needs, Walgreens services millions of people every day.
  • To find brands that fit your vibe, including the latest seasonal trends, visit a Walgreens near you.

MarketBeat Releases New Tools to Enhance Investment Strategies: 13F Filings and Congressional Trading Data

Retrieved on: 
Monday, March 11, 2024
Second Continental Congress, Holding, Congress, Politics, Security (finance)

SIOUX FALLS, S.D., March 11, 2024 /PRNewswire-PRWeb/ -- MarketBeat, a leading digital media company known for empowering individual investors, is thrilled to announce the launch of its latest suite of investment tools designed to provide unparalleled insights into the stock market. These tools focus on 13F filings and the trading activities of the top SEC 13F filers, along with comprehensive data on congressional trading, offering investors a cutting-edge advantage in navigating the complex world of investing.

Key Points: 
  • MarketBeat launches new tools for in-depth analysis of 13F filings and congressional trading, offering investors advanced insights.
  • These tools focus on 13F filings and the trading activities of the top SEC 13F filers, along with comprehensive data on congressional trading, offering investors a cutting-edge advantage in navigating the complex world of investing.
  • MarketBeat's innovative platform now includes detailed analyses of the latest filings and holdings of the top SEC 13F filers and congressional trading data.
  • 13F Filings and Top SEC 13F Filers' Holdings MarketBeat's innovative platform now includes detailed analyses of the latest filings and holdings of the top SEC 13F filers.